Company / Profit Margin
Protalix BioTherapeutics, Inc. Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
12.7%
FY2025
5-year range
-71.9% / 12.7%
FY2021-FY2025
Trend
+140.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has fluctuated over the past 9 years, ranging from -849.9% in FY2016 to 1329.9% in FY2017.
Based on SEC 10-K filings.
12.7% in FY2025 with a 5-year CAGR of +90.0%.
Improved from -71.9% to 12.7% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- +23.1pp
- 5-Year Change
- +90.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, profit margin increased 140.5% year-over-year.
- Peak profit margin was recorded in FY2017.
- Lowest profit margin in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 12.7% | +140.5% |
| FY2024 | -31.3% | +56.4% |
| FY2023 | -71.9% | -593.5% |
| FY2022 | -10.4% | +69.0% |
| FY2021 | -33.4% | +56.7% |
| FY2020 | -77.3% | +80.5% |
| FY2019 | -395.9% | -129.8% |
| FY2017 | 1329.9% | +256.5% |
| FY2016 | -849.9% | - |
| FY2015 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026